Medical - Devices
Compare Stocks
4 / 10Stock Comparison
EDAP vs NVCR vs ISRG vs IRTC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Medical - Devices
EDAP vs NVCR vs ISRG vs IRTC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $156M | $1.92B | $161.07B | $4.10B |
| Revenue (TTM) | $70M | $674M | $10.58B | $788M |
| Net Income (TTM) | $-13M | $-173M | $2.98B | $-28M |
| Gross Margin | 46.8% | 75.2% | 66.3% | 71.0% |
| Operating Margin | -38.2% | -27.2% | 30.5% | -3.3% |
| Forward P/E | — | — | 43.8x | — |
| Total Debt | $28M | $290M | $303M | $731M |
| Cash & Equiv. | $17M | $103M | $3.37B | $236M |
EDAP vs NVCR vs ISRG vs IRTC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Edap Tms S.a. (EDAP) | 100 | 154.1 | +54.1% |
| NovoCure Limited (NVCR) | 100 | 25.0 | -75.0% |
| Intuitive Surgical,… (ISRG) | 100 | 234.6 | +134.6% |
| iRhythm Technologie… (IRTC) | 100 | 100.5 | +0.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EDAP vs NVCR vs ISRG vs IRTC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
EDAP is the #2 pick in this set and the best alternative if income & stability is your priority.
- beta 0.77
- Beta 0.77 vs NVCR's 2.20
- +80.9% vs ISRG's -15.4%
NVCR lags the leaders in this set but could rank higher in a more targeted comparison.
ISRG carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 5.5% 10Y total return vs IRTC's 379.3%
- Lower volatility, beta 1.02, Low D/E 1.7%, current ratio 4.87x
- Better valuation composite
- 28.2% margin vs NVCR's -25.7%
IRTC is the clearest fit if your priority is growth exposure and defensive.
- Rev growth 26.2%, EPS growth 61.7%, 3Y rev CAGR 22.1%
- Beta 0.93, current ratio 4.63x
- 26.2% revenue growth vs NVCR's 8.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 26.2% revenue growth vs NVCR's 8.3% | |
| Value | Better valuation composite | |
| Quality / Margins | 28.2% margin vs NVCR's -25.7% | |
| Stability / Safety | Beta 0.77 vs NVCR's 2.20 | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +80.9% vs ISRG's -15.4% | |
| Efficiency (ROA) | 14.8% ROA vs EDAP's -18.8%, ROIC 15.0% vs -69.2% |
EDAP vs NVCR vs ISRG vs IRTC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
EDAP vs NVCR vs ISRG vs IRTC — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 3 of 6 categories
EDAP leads 0 • NVCR leads 0 • IRTC leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ISRG is the larger business by revenue, generating $10.6B annually — 152.0x EDAP's $70M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, EDAP holds the edge at +31.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $70M | $674M | $10.6B | $788M |
| EBITDAEarnings before interest/tax | -$24M | -$165M | $3.8B | -$6M |
| Net IncomeAfter-tax profit | -$13M | -$173M | $3.0B | -$28M |
| Free Cash FlowCash after capex | -$17M | -$48M | $2.8B | $19M |
| Gross MarginGross profit ÷ Revenue | +46.8% | +75.2% | +66.3% | +71.0% |
| Operating MarginEBIT ÷ Revenue | -38.2% | -27.2% | +30.5% | -3.3% |
| Net MarginNet income ÷ Revenue | -18.9% | -25.7% | +28.2% | -3.5% |
| FCF MarginFCF ÷ Revenue | -25.1% | -7.1% | +26.8% | +2.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +31.4% | +12.3% | +23.0% | +25.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.3% | -100.0% | +18.8% | +55.7% |
Valuation Metrics
Evenly matched — EDAP and NVCR and ISRG and IRTC each lead in 1 of 4 comparable metrics.
Valuation Metrics
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $156M | $1.9B | $161.1B | $4.1B |
| Enterprise ValueMkt cap + debt − cash | $166M | $2.1B | $158.0B | $4.6B |
| Trailing P/EPrice ÷ TTM EPS | -5.33x | -13.80x | 57.62x | -89.83x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 43.84x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.65x | — |
| EV / EBITDAEnterprise value multiple | — | — | 43.62x | — |
| Price / SalesMarket cap ÷ Revenue | 2.20x | 2.92x | 16.00x | 5.49x |
| Price / BookPrice ÷ Book value/share | 8.02x | 5.51x | 9.17x | 26.16x |
| Price / FCFMarket cap ÷ FCF | — | — | 64.67x | 118.84x |
Profitability & Efficiency
ISRG leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-65 for EDAP. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to IRTC's 4.79x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs EDAP's 3/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -65.4% | -50.8% | +16.9% | -20.6% |
| ROA (TTM)Return on assets | -18.8% | -16.5% | +14.8% | -2.8% |
| ROICReturn on invested capital | -69.2% | -16.4% | +15.0% | -5.2% |
| ROCEReturn on capital employed | -56.0% | -28.9% | +16.5% | -4.4% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 | 6 | 6 |
| Debt / EquityFinancial leverage | 1.43x | 0.85x | 0.02x | 4.79x |
| Net DebtTotal debt minus cash | $10M | $187M | -$3.1B | $495M |
| Cash & Equiv.Liquid assets | $17M | $103M | $3.4B | $236M |
| Total DebtShort + long-term debt | $28M | $290M | $303M | $731M |
| Interest CoverageEBIT ÷ Interest expense | -16.21x | -96.80x | — | -1.48x |
Total Returns (Dividends Reinvested)
ISRG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, EDAP leads with a +80.9% total return vs ISRG's -15.4%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.4% vs NVCR's -37.6% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +22.4% | +28.3% | -19.3% | -28.7% |
| 1-Year ReturnPast 12 months | +80.9% | +1.1% | -15.4% | -8.3% |
| 3-Year ReturnCumulative with dividends | -63.3% | -75.7% | +49.6% | -2.1% |
| 5-Year ReturnCumulative with dividends | -37.8% | -91.3% | +58.7% | +56.1% |
| 10-Year ReturnCumulative with dividends | +18.9% | +30.3% | +554.2% | +379.3% |
| CAGR (3Y)Annualised 3-year return | -28.4% | -37.6% | +14.4% | -0.7% |
Risk & Volatility
Evenly matched — EDAP and NVCR each lead in 1 of 2 comparable metrics.
Risk & Volatility
EDAP is the less volatile stock with a 0.77 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs IRTC's 58.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.77x | 2.20x | 1.02x | 0.93x |
| 52-Week HighHighest price in past year | $5.05 | $20.06 | $603.88 | $212.00 |
| 52-Week LowLowest price in past year | $1.21 | $9.82 | $427.84 | $112.31 |
| % of 52W HighCurrent price vs 52-week peak | +82.4% | +83.9% | +75.1% | +58.9% |
| RSI (14)Momentum oscillator 0–100 | 54.8 | 69.8 | 42.4 | 44.1 |
| Avg Volume (50D)Average daily shares traded | 38K | 1.5M | 1.8M | 524K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: EDAP as "Buy", NVCR as "Buy", ISRG as "Buy", IRTC as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 37.3% for ISRG (target: $623).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $6.00 | $33.50 | $622.60 | $193.67 |
| # AnalystsCovering analysts | 8 | 15 | 55 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.4% | 0.0% |
ISRG leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
EDAP vs NVCR vs ISRG vs IRTC: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is EDAP or NVCR or ISRG or IRTC a better buy right now?
For growth investors, iRhythm Technologies, Inc.
(IRTC) is the stronger pick with 26. 2% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Intuitive Surgical, Inc. (ISRG) offers the better valuation at 57. 6x trailing P/E (43. 8x forward), making it the more compelling value choice. Analysts rate Edap Tms S. a. (EDAP) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — EDAP or NVCR or ISRG or IRTC?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +58. 7%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus EDAP's +18. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — EDAP or NVCR or ISRG or IRTC?
By beta (market sensitivity over 5 years), Edap Tms S.
a. (EDAP) is the lower-risk stock at 0. 77β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 188% more volatile than EDAP relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 5% for iRhythm Technologies, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — EDAP or NVCR or ISRG or IRTC?
By revenue growth (latest reported year), iRhythm Technologies, Inc.
(IRTC) is pulling ahead at 26. 2% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: iRhythm Technologies, Inc. grew EPS 61. 7% year-over-year, compared to -52. 9% for Edap Tms S. a.. Over a 3-year CAGR, IRTC leads at 22. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — EDAP or NVCR or ISRG or IRTC?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -41. 5% for Edap Tms S. a. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -35. 6% for EDAP. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is EDAP or NVCR or ISRG or IRTC more undervalued right now?
Analyst consensus price targets imply the most upside for NVCR: 99.
0% to $33. 50.
07Which pays a better dividend — EDAP or NVCR or ISRG or IRTC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is EDAP or NVCR or ISRG or IRTC better for a retirement portfolio?
For long-horizon retirement investors, Intuitive Surgical, Inc.
(ISRG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 02), +554. 2% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ISRG: +554. 2%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between EDAP and NVCR and ISRG and IRTC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: EDAP is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; IRTC is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.